Glyco-therapy Biotechnology

Glyco-therapy Biotechnology is a China-based biotech company focused on next-generation multispecific conjugated therapeutics and enabling technologies for antibody conjugation. Founded in 2019 in Hangzhou, the company has built the proprietary YTConju™ glyco-editing, site-specific conjugation platform, which is designed to generate homogeneous and stable antibody-drug conjugates, antibody-oligonucleotide conjugates, and antibody-peptide/protein conjugates without requiring antibody re-engineering. In addition to internal therapeutic research, the company offers early-stage R&D services including ADC design, preparation, validation, and evaluation, and pursues licensing and co-development partnerships. Publicly visible evidence suggests the company remains primarily a platform and preclinical-stage organization rather than a clinically advanced therapeutic developer.